Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Zidavi is recommended by the Infectious Disease Society of America
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
Subscribe To Our Newsletter & Stay Updated